Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

osimertinib 1durvalumab 1anlotinib 1aflutinib 1Radiosurgery 1Monatide (IMS 3015) 1Immunotherapy 1Docetaxel 1Circulating Tumor DNA 1Chemotherapy, Adjuvant 1Biological Assay 1Adjuvants, Pharmaceutic 1AST5902 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Monatide (IMS 3015) × Thoracic × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡